HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...
BioAge Labs
BioAge Labs Partners with JiKang for APJ Agonist Nanobody License
US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...
BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets
US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...
BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman
NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...